Lite Strategy (LITS) Change in Account Payables (2010 - 2026)
Lite Strategy (LITS) posted quarterly Change in Account Payables of -$74000.0 for Q1 2026, up 82.34% year-over-year from -$40583.8 in Q1 2025, and up 55.69% quarter-over-quarter from -$167000.0 in Q4 2025.
Lite Strategy (LITS) Change in Account Payables (2010 - 2026) Analysis & Trends
Lite Strategy's Change in Account Payables history runs 17 years deep, the most recent figure standing at -$74000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables rose 82.34% year-over-year to -$74000.0; the TTM figure through Mar 2026 stood at $76000.0 (up 102.56% YoY), while the FY2025 annual figure was -$3.0 million, up 4.93% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$74000.0, up from -$167000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $2.0 million in Q1 2022, with the low at -$4.4 million in Q4 2022.
- The 5-year median for Change in Account Payables is -$74000.0 (2026), against an average of -$363764.7.
- The sharpest annual moves came in 2022 and 2023: Change in Account Payables surged 12406.25% in 2022, then slumped 684.2% in 2023.
- Lite Strategy's Change in Account Payables stood at -$4.4 million in 2022, then soared by 57.83% to -$1.8 million in 2023, then surged by 79.29% to -$380000.0 in 2024, then soared by 56.05% to -$167000.0 in 2025, then surged by 55.69% to -$74000.0 in 2026.
- Business Quant data shows LITS's Change in Account Payables at -$74000.0 in Q1 2026, -$167000.0 in Q4 2025, and $318000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | -74,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74,000.00 |
| Mar 31, 2026 | -74,000.00 |
| Dec 31, 2025 | -167,000.00 |
| Dec 31, 2025 | -167,000.00 |
| Sep 30, 2025 | 318,000.00 |
| Sep 30, 2025 | 318,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | -419,000.00 |
| Mar 31, 2025 | -419,000.00 |
| Dec 31, 2024 | -380,000.00 |
| Dec 31, 2024 | -380,000.00 |
| Sep 30, 2024 | -2.19 Mn |
| Sep 30, 2024 | -2.19 Mn |
| Jun 30, 2024 | 19,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Mar 31, 2024 | 1.59 Mn |
| Mar 31, 2024 | 1.59 Mn |
| Dec 31, 2023 | -1.84 Mn |
| Dec 31, 2023 | -1.84 Mn |